<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        218-368-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DAPOX 60MG F.C.TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DAPOXETINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        52.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BX14 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dapox&trade; contains an active substance called &lsquo;dapoxetine&rsquo;. This belongs to a<br />group of medicines called &lsquo;selective serotonin reuptake inhibitors&rsquo; (SSRIs).<br />Dapox&trade; may also be known as a &lsquo;urological&rsquo; medicine.<br />Dapox&trade; increases the time it takes to ejaculate and can improve the control<br />over the ejaculation. This may reduce the frustration or worry about fast<br />ejaculation.<br />Dapox&trade; is used to treat premature ejaculation in adult men aged 18 to 64<br />years.<br />Premature ejaculation is when a man ejaculates with little sexual stimulation<br />and before the man wants. This can cause problems for the man and may<br />cause problems in sexual relationships.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>you are allergic to dapoxetine or any of the other ingredients of this<br />medicine (listed in section 6)<br />&bull; you have heart problems, such as heart failure or problems with the heart<br />rhythm<br />&bull; you have a history of fainting<br />&bull; you have ever had mania (symptoms include feeling over-excited, irritable<br />or not being able to think clearly) or severe depression<br />&bull; you have moderate or severe liver problems.<br />&bull; you are taking:<br />- Medicines for depression called &lsquo;monoamine oxidase inhibitors&rsquo; (MAOIs)<br />- Thioridazine used for schizophrenia<br />- Other medicines for depression<br />- Lithium (a medicine for bipolar disorder)<br />- Linezolid (an antibiotic used to treat infections)<br />- Tryptophan (a medicine to help you sleep)<br />- St John&rsquo;s wort (a herbal medicine)<br />- Tramadol (used to treat serious pain)<br />- Medicines used to treat migraines.<br />Do not take Dapox&trade; at the same time as any of the medicines listed above.<br />If you have taken any of these medicines, you will need to wait 14 days after<br />you stop taking it before you can start taking Dapox&trade;. Once you have<br />stopped taking Dapox&trade;, you will need to wait 7 days before taking any of<br />the medicines listed above. If you are not sure about what to do, talk to your<br />doctor or pharmacist before taking this medicine.<br />&bull; Certain medicines for fungal infection, including ketoconazole and<br />itraconazole<br />&bull; Certain medicines for HIV, including ritonavir, saquinavir, nelfinavir and<br />atazanavir<br />&bull; Certain antibiotics for treating infection, including telithromycin<br />&bull; Nefazodone (an antidepressant)<br />Also see section &ldquo;Other medicines and Dapox&trade; &rdquo;.<br />Do not take this medicine if any of the above apply to you. If you are not<br />sure, talk to your doctor or pharmacist before taking this medicine.<br />Children and adolescents<br />This medicine should not be used in children or adolescents under age 18<br />years.<br />Warnings and precautions<br />Talk to your doctor, pharmacist or nurse before taking Dapox&trade; if:<br />&bull; You have not been diagnosed with premature ejaculation<br />&bull; You also have another sexual problem, such as erectile dysfunction<br />&bull; You have a history of dizziness from low blood pressure<br />&bull; You use recreational drugs such as ecstasy, LSD, narcotics or<br />benzodiazepines<br />&bull; You drink alcohol (see section &ldquo;Dapox&trade; with food, drink and alcohol&rdquo;)<br />&bull; You have ever had a mental health problem such as depression, mania<br />(symptoms include feeling over excited, irritable or not being able to think<br />clearly), bipolar disorder (symptoms include serious mood swings between<br />mania and depression) or schizophrenia (a psychiatric disease)<br />&bull; You have epilepsy<br />&bull; You have a history of bleeding or blood clotting problems<br />&bull; You have kidney problems<br />&bull; You have, or are at risk of, high pressure in the eye (glaucoma).<br />If any of the above apply to you (or you are not sure), talk to your doctor or<br />pharmacist before taking this medicine.<br />Before you start taking this medicine, your doctor should perform a test to<br />make sure that your blood pressure doesn&rsquo;t drop too much when you stand<br />up from lying down.<br />Other medicines and Dapox&trade;<br />Tell your doctor or pharmacist if you are taking, have recently taken, or<br />might take any other medicines. This includes medicines you get without a<br />prescription, such as herbal medicines. This is because Dapox&trade; can affect<br />the way some other medicines work. Also some other medicines can affect<br />the way Dapox&trade; works. Therefore, use of other medicines may affect the<br />maximum dose of Dapox&trade; you&rsquo;re allowed to take.<br />Do not take Dapox&trade; at the same time as any of the following medicines:<br />&bull; Medicines for depression called &lsquo;monoamine oxidase inhibitors&rsquo; (MAOIs)<br />&bull; Thioridazine used for schizophrenia<br />&bull; Other medicines for depression<br />&bull; Lithium (a medicine for bipolar disorder)<br />&bull; Linezolid (an antibiotic used to treat infections)<br />&bull; Tryptophan (medicine to help you sleep)<br />&bull; St John&rsquo;s wort (a herbal medicine)<br />&bull; Tramadol (used to treat serious pain)<br />&bull; Medicines used to treat migraines.<br />Do not take Dapox&trade; at the same time as any of the medicines listed above.<br />If you have taken any of these medicines, you will need to wait 14 days after<br />you stop taking it before you can start taking Dapox&trade;. Once you have<br />stopped taking Dapox&trade;, you will need to wait 7 days before taking any of<br />the medicines listed above. If you are not sure about what to do, talk to your<br />doctor or pharmacist before taking this medicine.<br />&bull; Certain medicines for fungal infection, including ketoconazole and<br />itraconazole<br />&bull; Certain medicines for HIV, including ritonavir, saquinavir, nelfinavir and<br />atazanavir<br />&bull; Certain antibiotics for treating infection, including telithromycin<br />&bull; Nefazodone (an antidepressant)<br />Tell your doctor or pharmacist if you are taking any of the following<br />medicines:<br />&bull; Medicines for mental health problems other than depression<br />&bull; Non steroidal anti-inflammatory medicines such as ibuprofen or<br />acetylsalicyclic acid<br />&bull; Medicines to thin your blood, such as warfarin<br />&bull; Certain medicines used to treat erectile dysfunction, such as sildenafil,<br />tadalafil or vardenafil, as these medicines may lower your blood pressure,<br />possibly upon standing<br />&bull; Certain medicines used to treat high blood pressure and chest pain (angina)<br />(such as verapamil and diltiazem), or enlarged prostate, as these medicines<br />may also lower your blood pressure, possibly upon standing<br />&bull; Certain other medicines for fungal infection, such as fluconazole<br />&bull; Certain other medicines for HIV, such as amprenavir and fosamprenavir<br />&bull; Certain other antibiotics for treating infection, such as erythromycin and<br />clarithromycin<br />&bull; Aprepitant (used to treat nausea).<br />If you are not sure if any of the above apply to you, talk to your doctor or<br />pharmacist before taking this medicine.<br />Dapox&trade; with food, drink and alcohol<br />&bull; This medicine can be taken with or without food.<br />&bull; You should take this medicine with at least one full glass of water.<br />&bull; Avoid alcohol when taking this medicine.<br />&bull; The effects of alcohol such as feeling dizzy, sleepy and having slow<br />reactions, may be increased if taken with this medicine.<br />&bull; Drinking alcohol while taking this medicine may increase your risk of<br />injury from fainting or from other side effects.<br />Pregnancy, breast-feeding and fertility<br />This medicine should not be taken by women.<br />Driving and using machines<br />You may feel sleepy, dizzy, faint, have difficulty concentrating and blurred<br />vision while taking this medicine. If you experience any of these or similar<br />effects, you should avoid driving or operating hazardous machinery. The<br />effects of alcohol may be increased if taken with this medicine and you may<br />be more at risk of injury from fainting or from other side effects if you take<br />this medicine with alcohol.<br />Dapox&trade; contains lactose<br />This medicine contains lactose (a type of sugar). If you have been told by<br />your doctor that you have an intolerance to some sugars, contact your doctor<br />before taking this medicine.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>3. How to take Dapox&trade;<br />Always take this medicine exactly as your doctor or pharmacist has told you.<br />Check with your doctor or pharmacist if you are not sure.<br />&bull; The recommended dose is 30 mg. Your doctor may increase the dose to<br />60 mg.<br />&bull; Only take the medicine 1 to 3 hours before sexual activity is anticipated.<br />&bull; Do not take this medicine more than once every 24 hours or every day.<br />&bull; Swallow the tablets whole to avoid a bitter taste, with at least one full glass<br />of water. This may help lower your chance of fainting (see &lsquo;Fainting and low<br />blood pressure&rsquo; in section 4).<br />&bull; This medicine can be taken with or without food.</p><p>&bull; This medicine should not be used by men under 18 or over 65 years of<br />age.<br />&bull; Discuss your Dapox&trade; treatment with your doctor after the first 4<br />weeks or after 6 doses to see whether you should continue treatment. If<br />treatment is continued, you should see your doctor again to discuss this<br />at least every six months.<br />If you take more Dapox&trade; than you should<br />Tell your doctor or pharmacist if you have taken more tablets than you<br />should. You may feel sick or be sick.<br />If you stop taking Dapox&trade;<br />Talk to your doctor before you stop taking this medicine. You may have<br />problems sleeping and feel dizzy after you stop taking this medicine,<br />even if you have not taken it every day.<br />If you have any further questions on the use of this medicine, ask your<br />doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not<br />everybody gets them.<br />Stop taking Dapox&trade; and see your doctor straight away if:<br />&bull; You have fits (seizures)<br />&bull; You faint or feel light headed when you stand up<br />&bull; You notice any changes in your mood<br />&bull; You have any thoughts of suicide or harming yourself.<br />If you notice any of the above, stop taking this medicine and see your<br />doctor straight away.<br />Fainting and low blood pressure<br />This medicine can make you faint or make your blood pressure drop<br />when you stand up. To help lower the chance of this happening:<br />&bull; Take this medicine with at least one full glass of water.<br />&bull; Do not take this medicine if you are dehydrated (you do not have<br />enough water in your body). This can happen if:<br />- You have not had anything to drink in the past 4 to 6 hours<br />- You have been sweating for a long time<br />- You have an illness where you have a high temperature, diarrhoea or<br />being sick.<br />&bull; If you feel like you might faint (such as feeling sick, feeling dizzy,<br />light headed, confused, sweaty or an abnormal heart beat), or feel light<br />headed when you stand up, immediately lie down so your head is lower<br />than the rest of your body or sit down with your head between your<br />knees until you feel better. This will stop you from falling and hurting<br />yourself if you do faint.<br />&bull; Do not stand up quickly after you have been sitting or lying down for a<br />long time.<br />&bull; Do not drive or use any tools or machines if you feel faint when taking<br />this medicine.<br />&bull; Tell your doctor if you faint when taking this medicine.<br />Very common side effects (may affect more than 1 in 10 men):<br />&bull; Feeling dizzy<br />&bull; Headache<br />&bull; Feeling sick.<br />Common side effects (may affect up to 1 in 10 men):<br />&bull; Feeling irritable, anxious, agitated or restless<br />&bull; Feeling numb or having &lsquo;pins and needles&rsquo;<br />&bull; Difficulty getting or keeping an erection<br />&bull; Sweating more than normal or flushing<br />&bull; Diarrhoea, constipation or having wind<br />&bull; Stomach pain, bloating or being sick<br />&bull; Problems sleeping or strange dreams<br />&bull; Feeling tired or sleepy, yawning<br />&bull; Blocked nose (nasal congestion)<br />&bull; A rise in blood pressure<br />&bull; Difficulty concentrating<br />&bull; Shaking or trembling<br />&bull; Lower interest in sex<br />&bull; Ringing in the ears<br />&bull; Blurred vision<br />&bull; Indigestion<br />&bull; Dry mouth.<br />Uncommon side effects (may affect up to 1 in 100 men):<br />&bull; Fainting or feeling dizzy upon standing (see advice above)<br />&bull; Change in mood, feeling overly excited or feelings of paranoia<br />&bull; Feeling confused, disoriented or unable to think clearly<br />&bull; Slow or irregular heartbeat or increase in heart rate<br />&bull; Loss of sex drive, problems reaching orgasm<br />&bull; Feeling weak, sedated, lethargic or fatigued<br />&bull; Feeling depressed, nervous or indifferent<br />&bull; Feeling hot, jittery, abnormal or drunk<br />&bull; Vision problems, eye pain or dilated pupils<br />&bull; Low or high blood pressure<br />&bull; Feeling itchy or cold sweat<br />&bull; Spinning sensation<br />&bull; Abnormal taste<br />&bull; Teeth grinding.<br />Rare side effects (may affect up to 1 in 1,000 men):<br />&bull; Feeling dizzy following exertion<br />&bull; Sudden onset of sleep<br />&bull; Urgency of bowel action.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This<br />includes any possible side effects not listed in this leaflet.<br />By reporting side effects you can help provide more information on the<br />safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of reach and sight of children.<br />Do not store above 30 &ordm;C.<br />Do not use this medicine after the expiry date which is stated on the<br />carton after EXP.<br />Do not throw away any medicines via wastewater or household waste.<br />Ask your pharmacist how to throw away medicines you no longer use.<br />These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Dapox&trade; contains<br />The active substance is dapoxetine. Each film coated tablet contains<br />30 mg or 60 mg dapoxetine as a hydrochloride salt.<br />The other ingredients are:<br />Tablet core: lactose monohydrate, microcrystalline cellulose,<br />croscarmellose sodium, colloidal silicon dioxide, magnesium stearate.<br />Tablet coating: lactose monohydrate, hypromellose, titanium dioxide,<br />triacetin, iron oxide black and iron oxide yellow.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                coated tablets, debossed with 'JPAV' one side and plain on other side.
Dapox™ 60 mg film-coated tablets are grey, round shaped, film coated
tablets, debossed with 'JPAW' one side and plain on other side.
Dapox™ film-coated tablets available in 30 mg and 60 mg tablets in
boxes of 4 tablets each.
Not all pack may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Factory Co.,<br />Jeddah, Makkah Region, Saudi Arabia.<br />Tel: +966-12-6081111<br />Fax: +966-12-6081222<br />Website: www.jamjoompharma.com<br />Please report adverse drug events to:<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance Centre (NPC):<br />o Fax: +966-11-205-7662<br />o SFDA Call Center: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: https://ade.sfda.gov.sa<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>یحتوي دابوكس&nbsp;على مادة فعَّالة تُسمى &quot;دابوكسیتین&quot;. ینتمي دابوكس&nbsp;إلى مجموعة من&nbsp;الأدویة تعرف باسم &quot;مثبطات إعادة امتصاص السیروتونین الانتقائية&nbsp;(SSRIs)&nbsp;كما قد&nbsp;</p><p>یُعرَف دابوكس&nbsp;على أنھ دواء &quot;للجھاز البولي&quot;.</p><p>من الوقت المستغرق للقذف، كما یمكنھ أن یحسٍّن التحكم في عملیة القذف. &trade; یزید دابوكس<br />وھذا قد یحد من الإحباط أو القلق حیال سرعة القذف.<br />لعلاج سرعة القذف عند الرجال البالغین الذین تتراوح أعمارھم من &trade; یستخدم دابوكس<br />ثمانیة عشر عامًا إلى أربعة وستین عامًا.<br />یحدث القذف السریع عندما یقذف الرجل مع التَّعرض لإثارة جنسیة بسیطة أو قبل الوقت<br />الذي یرغب فیھ بذلك. یمكن أن یُسبب ھذا مشاكل للرجل وقد یتسبب في مشاكل أثناء<br />العلاقات الجنسیة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول دابوكس<br />&bull; إذا كنت تعاني من حساسیة تجاه دابوكسیتین أو تجاه أي مكون من المكونات الأخرى<br />.( الداخلة بتركیب ھذا الدَّواء (المدرجة في قسم رقم ٦<br />&bull; إذا كنت تعاني من مشاكل بالقلب مثل ھبوط القلب (السكتة القلبیة) أو أي مشكلة من<br />مشاكل في إیقاع نبض القلب.<br />&bull; إذا كان لدیك تاریخ مرضي من الإغماء.<br />&bull; إذا كنت قد أُصبت من قبل بالھوس (تشمل الأعراض: الشعور بفرط الاستثارة أو الشعور<br />بالعصبیة أو عدم القدرة على التفكیر بوضوح) أو إذا كنت قد عانیت من اكتئاب شدید.<br />&bull; إذا كنت تعاني من مشاكل متوسطة أو شدیدة الخطورة بالكبد.<br />&bull; إذا كنت تتناول أي من الأدویة التالیة:<br />- أدویة علاج الاكتئاب التي تسمى &quot;مثبطات أوكسیدیز أحادي الأمین&quot;.<br />- ثیوریدازین المستخدم لعلاج الفصام.<br />- أدویة أخرى لعلاج الاكتئاب.<br />- اللیثیوم (دواء لعلاج الاضطِّراب ثنائي القطب).<br />- لینزولید (مضاد حیوي یستخدم لعلاج العدوى).<br />- تربتوفان (دواء یساعد على النوم).<br />- نبتة سانت جونز (دواء عشبي)<br />- ترامادول (مسكن للألم) (یُستخدم لعلاج الآلام الخطیرة).<br />- الأدویة المستخدمة لعلاج الصداع النصفي.<br />ا من ھذه 􀌒 بالتزامن مع الأدویة الأخرى المدرجة أعلاه. إذا تناولت أی &trade; لا تتناول دابوكس<br />الأدویة، فستحتاج إلى الانتظار لمدة ۱٤ یومًا بعد التَّوقف عن تناولھا قبل أن یمكنك البدء في<br />فستحتاج إلى الانتظار سبعة أیام قبل ،&trade; بمجرد التَّوقف عن تناول دابوكس .&trade; تناول دابوكس<br />تناول أيٍّ من الأدویة المدرجة أعلاه. إذا لم تكن متأكدًا مما یجب علیك فعلھ، فیُرجى التَّحدث<br />إلى الطبیب المعالج لك أو الصیدلي الخاص بك قبل تناول ھذا الدَّواء.<br />&bull; أدویة معینة لعلاج العدوى الفطریة، بما في ذلك كیتوكونازول وإتراكونازول.<br />&bull; بعض أدویة علاج فیروس نقص المناعة البشریة بما في ذلك ریتونافیر وساكوینافیر<br />ونیلفینافیر وأتازانافیر.<br />&bull; بعض المضادات الحیویة لعلاج العدوى بما في ذلك تیلیثرومایسین.<br />&bull; نیفازودون (دواء مضاد للاكتئاب)<br />.&quot;&trade; انظر أیضًا قسم: &quot;تناول الأدویة الأخرى مع دابوكس<br />لا تتناول ھذا الدَّواء، إذا كان أي من الحالات أعلاه تنطبق علیك. إذا لم تكن متأكدًا فتحدَّث<br />إلى الطبیب المعالج لك أو الصیدلي الخاص بك قبل تناول ھذا الدَّواء.<br />الأطفال والمراھقون<br />یحذر على الأطفال أو المراھقین الذین تقل أعمارھم عن ۱۸ عامًا استخدام ھذا الدواء.<br />تحذیرات واحتیاطات<br />تحدث إلى الطبیب المعالج لك أو الصیدلي الخاص بك أو الممرض(ة) المتابع(ة) لك قبل<br />في الحالات الآتیة: &trade; تناوُل دابوكس<br />&bull; إذا لم یكن قد تم تشخیص إصابتك بسرعة القذف.<br />&bull; إذا كنت تعاني من مشكلة أخرى أثناء الجماع مثل: ضعف الانتصاب.<br />&bull; إذا كان لدیك تاریخ مرضي من الإصابة بالدوخة نتیجة لانخفاض ضغط الدَّم.<br />&bull; إذا كنت تستخدم بعض العقاقیر لأغراض تروحیة مثل: إكستاسي أو إل إس دي أو الأدویة<br />المخدرة أو البِنزودیازیبینات.<br />مع الأطعمة والمشروبات &trade; &bull; إذا كنت تشرب الكحولیات (انظر قسم: &quot;تناول دابوكس<br />والكحولیات&quot;).<br />&bull; إذا كنت قد أصبت من قبل بمشاكل في الصحة العقلة مثل: اكتئاب وھوس (تشمل<br />الأعراض الشعور بفرط الاستثارة أو الشعور بالعصبیة أو عدم القدرة على التفكیر<br />بوضوح)، الاضطراب ثنائي القطب (تشمل الأعراض التقلبات المزاجیة الخطیرة من<br />الھوس إلى الاكتئاب) أو الفصام (أحد الأمراض النفسیة).<br />&bull; إذا كنت تعاني من مرض الصرع.<br />&bull; إذا كان لدیك تاریخ مرضي من الإصابة بالنزیف أو بمشكلات تجلط الدَّم.<br />&bull; إذا كنت تُعاني من مشاكل بالكلى.<br />&bull; إذا كنت تعاني من ارتفاع الضغط في العین (الزَّرَق)، أو إذا كنت معرضًا لخطر الإصابة<br />بھا.<br />إذا لم تكن متأكدًا مما إذا كان ینطبق علیك أيٌّ مما سبق، فیُرجى التَّحدث إلى الطبیب المعالج<br />لك أو الصیدلي الخاص بك قبل تناول ھذا الدَّواء.<br />قبل البدء في تناول ھذا الدَّواء، یجب أن یقوم الطبیب المعالج لك بإجراء اختبار؛ للتأكد من<br />عدم انخفاض ضغط الدَّم لدیك بشدة عند النھوض من وضعیة الاستلقاء.<br />&trade; تناول الأدویة الأخرى مع دابوكس<br />أخبر الطبیب المعالج لك أو الصیدلي الخاص بك إذا كنت تتناول أو قد تناولت مؤخرًا أو قد<br />تتناول أیة أدویة أخرى. یشمل ھذا الأدویة التي تتناولھا بدون وصفة طبیة مثل الأدویة<br />قد یؤثر على آلیة عمل بعض الأدویة الأخرى. وبالمثل، فقد تُؤثر &trade; العشبیة. لأن دابوكس<br />ومن ثم، فقد یُؤثر استخدام أدویة أخرى .&trade; بعض الأدویة الأخرى على آلیة عمل دابوكس<br />.&trade; على الجرعة القصوى المسموح لك بتناولھا من دابوكس<br />في نفس وقت تناول الأدویة التَّالیة: &trade; لا تتناول دابوكس<br />&bull; أدویة لعلاج الاكتئاب تسمى &quot;مثبطات أوكسیدیز أحادي الأمین&quot;.<br />&bull; ثیوریدازین المستخدم لعلاج الفصام.<br />&bull; أدویة أخرى لعلاج الاكتئاب.<br />&bull; لیثیوم (دواء یستخدم لعلاج الاضطِّراب ثنائي القطب).<br />&bull; لینزولید (مُضاد حیوي یُستخدم لعلاج العدوى).<br />&bull; تربتوفان (دواء لمساعدتك على النوم).<br />&bull; نبتة سانت جونز (عشبة طبیة).<br />&bull; ترامادول (دواء یستخدم لعلاج الآلام الشدیدة).<br />&bull; الأدویة المستخدمة لعلاج الصداع النصفي.<br />ا من 􀌒 في الوقت نفسھ مع الأدویة الأخرى المدرجة أعلاه. إذا تناولت أی &trade; لا تتناول دابوكس<br />ھذه الأدویة، فستحتاج إلى الانتظار ۱٤ یومًا بعد التَّوقف عن تناولھا قبل أن یمكنك البدء في<br />فستحتاج إلى الانتظار سبعة أیام قبل ،&trade; بمجرد التَّوقف عن تناول دابوكس .&trade; تناول دابوكس<br />تناول أيٍّ من الأدویة المدرجة أعلاه. إذا لم تكن متأكدًا مما یجب علیك فعلھ، فیُرجى التَّحدث<br />إلى الطبیب المعالج لك أو الصیدلي الخاص بك قبل تناول ھذا الدَّواء.<br />&bull; أدویة معینة لعلاج العدوى الفطریة بما في ذلك كیتوكونازول وإتراكونازول.<br />&bull; أدویة معینة لعلاج فیروس نقص المناعة البشریة، بما في ذلك ریتونافیر وساكوینافیر<br />ونیلفینافیر وأتازانافیر.<br />&bull; مضادات حیویة معینة لعلاج العدوى وتشمل: تیلیثرومایسین.<br />&bull; نیفازودون (ھوعلاج مضاد للاكتئاب).<br />ا من الأدویة التَّالیة: 􀌒 أخبر الطبیب المعالج لك أو الصیدلي الخاص بك إذا كنت تتناول أی<br />&bull; أدویة علاج الاضطرابات الصحیة العقلیة بخلاف الاكتئاب.<br />&bull; الأدویة غیر السیترویدیة المضادة للالتھابات، مثل إیبوبروفین أو حمض أسیتیل<br />سالیسیلیك.<br />&bull; الأدویة المسیلة للدَّم مثل وارفارین.<br />&bull; أدویة معینة لعلاج ضعف الانتصاب مثل سیلدینافیل أو تادالافیل أو فاردینافیل، إذ یمكن<br />لھذه الأدویة أن تقلل ضغط الدَّم لدیك خاصة عند الوقوف.<br />&bull; أدویة معینة تستخدم لعلاج ارتفاع ضغط الدم وألم الصدر (الذبحة الصدریة) (مثل<br />فیرابامیل ودیلتیازم) أو تضخم البروستاتا؛ إذ قد تقلل ھذه الأدویة بدورھا من ضغط الدَّم<br />لدیك عند الوقوف<br />&bull; أدویة معینة أخرى لعلاج العدوى الفطریة مثل فلوكونازول.<br />&bull; أدویة معینة أخرى لعلاج فیروس نقص المناعة البشریة مثل أمبرینافیر وفوسامبرینافیر.<br />&bull; مضادات حیویة معینة أخرى لعلاج العدوى مثل إریثرومیسین و كلاریثرومایسین.<br />&bull; أبریبیتانت (دواء یستخدم في علاج الغثیان).<br />ا مما سبق، فیُرجى التَّحدث إلى الطبیب المعالج 􀌒 إذا لم تكن متأكدًا مما إذا كان ینطبق علیك أی<br />لك أو الصیدلي الخاص بك قبل تناول ھذا الدَّواء.<br />مع الأغذیة والمشروبات والكحولیات &trade; تناوُل دابوكس<br />&bull; یمكن تناول ھذا الدَّواء مع الطعام أو بدونھ.<br />&bull; یجب علیك تناول ھذا الدَّواء مع كوب كامل من الماء على الأقل.<br />&bull; تجنب تناول الكحولیات عند تناول ھذا الدَّواء، فقد تزید من تأثیرات الكحولیات مثل<br />الشعور بالدوخة والنعاس وبطء رد الفعل، إذا تم تناولھا مع ھذا الدَّواء.<br />&bull; قد یزید تناول الكحولیات مع ھذا الدَّواء من خطر التَّعرض للإصابات بسبب الإغماء، أو<br />بسبب آثار جانبیة أخرى.<br />الحمل والرضاعة الطبیعیة والخصوبة<br />یجب على السیدات تجنب تناول ھذا الدَّواء.<br />القیادة واستخدام الآلات<br />قد تشعر بالنُّعاس والدوخة والإغماء وبصعوبة في التركیز وبعدم وضوح الرؤیة أثناء تناول<br />ھذا الدَّواء. إذا عانیت من أي من ھذه الآثار أو من آثار مماثلة، فیجب علیك تجنب القیادة أو<br />تشغیل الآلات الخطیرة. فقد تزداد تأثیرات الكحولیات إذا تم تناولھا مع ھذا الدَّواء، وقد<br />تصبح أكثر عرضة لخطر الإصابة بسبب الإغماء أو بسبب آثار جانبیة أخرى إذا تناولت<br />ھذا الدَّواء مع الكحولیات.<br />على اللاكتوز &trade; یحتوي دابوكس<br />یحتوي ھذا الدَّواء على لاكتوز (نوع من السكر). إذا كان الطبیب المعالج لك قد أخبرك بأنك<br />لا تتحمل بعض أنواع السكریات، فاتصل بھ قبل تناول ھذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دائمًا ھذا الدَّواء بالضبط حسب تعلیمات الطبیب المعالج لك أو الصیدلي الخاص بك.<br />یُرجى استشارة الطبیب المعالج لك أو الصیدلي الخاص بك إذا لم تكن متأكدًا من كیفیة<br />التناوُل.<br />&bull; الجُرعة المُوصى بھا ھي ۳۰ ملجم وقد یُزید الطبیب المعالج لك الجرعة إلى ٦۰ ملجم<br />یومیًا.<br />&bull; لا تتناول الدَّواء إلا قبل الجماع بمدة تتراوح بین ساعة إلى ۳ ساعات.<br />&bull; لا تتناول ھذا الدَّواء أكثر من مرة كل أربع وعشرین ساعة أو كل یوم.<br />&bull; ابتلع الأقراص كاملة؛ لتجنب الطعم المر مع كوب كامل على الأقل من الماء. حیث قد<br />یُساعد ھذا على تقلیل احتمالیة إصابتك بالإغماء (انظر &quot;الإغماء وانخفاض ضغط الدَّم&quot; في<br />.( قسم</p><p>یمكن تناول ھذا الدَّواء مع الطعام أو بدونھ.<br />&bull; یجب عدم استخدام ھذا الدَّواء من قبل الرجال الذین تقل أعمارھم عن ثمانیة عشر عامًا أو<br />الذین تزید أعمارھم على خمسة وستین عامًا.<br />بعد الأسابیع الأربع الأولى من العلاج أو &trade; &bull; ناقش مع الطبیب المعالج لك العلاج ب دابوكس<br />بعد ست جرعات منھ لترى ما إذا كان علیك الاستمرار في العلاج أم لا. في حالة مواصلة<br />العلاج، یجب علیك زیارة الطبیب المعالج لك مجددًا لمناقشتھ كل ستة أشھر على الأقل.<br />&trade; إذا تناولت كمیة أكثر مما یجب من دابوكس<br />أخبر طبیب المعالج لك أو الصیدلي إذا كنت قد تناولت كمیة من الأقراص أكثر مما یجب. قد<br />تشعر بالإعیاء أو تصاب بھ.<br />&trade; إذا توقفت عن تناوُل دابوكس<br />تحدَّث إلى الطبیب المعالج لك قبل التَّوقف عن تناول ھذا الدَّواء. قد تجد صعوبة في النوم<br />ا. 􀌒 وتشعر بالدوخة بعد التَّوقف عن تناول ھذا الدَّواء حتى إذا لم تكن قد تناولتھ یومی<br />استشر الطبیب المعالج لك أو الصیدلي الخاص بك إذا كنت بحاجة إلى أیة أسئلة إضافیة متعلقة<br />باستخدام ھذا الدَّواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد یُسبب ھذا الدواء آثارًا جانبیة مثل كافة الأدویة، على الرغم من عدم حدوثھا لكافة المرضى.<br />وقم بزیارة الطبیب المعالج لك على الفور في الحالات التَّالیة: &trade; توقف عن تناول دابوكس<br />&bull; إذا كنت تُعاني من نوبات تشنجیة.<br />&bull; إذا كنت تصاب بالإغماء أو تشعر بدوار عند الوقوف.<br />&bull; إذا لاحظت أي تغیرات تطرأ على حالتك المزاجیة.<br />&bull; إذا كانت لدیك أیة أفكار متعلقة بالانتحار أو إیذاء نفسك.<br />ا مما سبق، فتوقف عن تناول ھذا الدَّواء وقم بزیارة الطبیب المعالج لك على 􀌒 إذا لاحظت أی<br />الفور.<br />الإغماء وانخفاض ضغط الدَّم<br />قد یصیبك ھذا الدَّواء بالإغماء أو ھبوط في ضغط الدَّم عند الوقوف. لتقلیل احتمالیة حدوث<br />ذلك، اتبع ما یلي:<br />&bull; تناول ھذا الدَّواء على الأقل مع كوب كامل من الماء.<br />&bull; لا تتناول ھذا الدَّواء إذا كنت تعاني من الجفاف (لیس لدیك كمیة كافیة من الماء بجسمك). قد<br />یحدث ھذا في الحالات التَّالیة:<br />٦ ساعات الماضیة. - &bull; إذا لم تكن قد تناولت أیة مشروبات خلال ٤<br />&bull; إذا كنت تتعرق لفترة طویلة.<br />&bull; إذا كنت مصابًا بمرض تعاني فیھ من ارتفاع درجة الحرارة أو الإسھال أو الإعیاء.<br />&bull; إذا كنت تشعر بأنك قد تصاب بالإغماء (كالشعور بالإعیاء أو الشعور بالدوخة أو الدوار أو<br />الارتباك أو التَّعرق أو اضطراب ضربات القلب) أو تشعر بالدوار عند الوقوف، استلقِ على<br />الفور بحیث تكون رأسك منخفضة عن باقي جسمك أو اجلس واضعًا رأسك بین ركبتیك إلى أن<br />تشعر بتحسن. سیمنعك ھذا من السقوط وإیذاء نفسك إذا أصبت بالإغماء.<br />&bull; لا تقف سریعًا بعد الجلوس أو الاستلقاء لوقت طویل.<br />&bull; تجنب القیادة أو استخدام الأدوات أو الماكینات إذا شعرت بالإغماء عند تناول ھذا الدَّواء.<br />&bull; أخبر الطبیب المعالج لك إذا أصبت بالإغماء عند تناول ھذا الدَّواء.<br />دا، قد تُؤثر على أكثر من مریض من بین كل ۱۰ مرضى: 􀌒 آثار جانبیة شائعة ج<br />&bull; شعور بالدوخة.<br />&bull; صداع<br />&bull; الشعور بالإعیاء.<br />آثار جانبیة شائعة (قد تُؤثر على ما یصل إلى مریض واحد من بین كل ۱۰ مرضى):<br />&bull; شعور بالعصبیة أو قلق أو ھیاج أو تَّململ.<br />&bull; شعور بتَّنمیل أو بوخز مثل وخز &quot;الإبر أو المسامیر&quot;.<br />&bull; ضعف في الانتصاب أو الحفاظ على الانتصاب.<br />&bull; تعرق أكثر من الطبیعي أو احمرار بالجلد.<br />&bull; إسھال أو إمساك أو غازات.<br />&bull; شعور بألم بالمعدة أو انتفاخ أو إعیاء.<br />&bull; مشاكل في النوم أو أحلام غریبة.<br />&bull; شعور بالتَّعب أو النُّعاس أو التثاؤب.<br />&bull; انسداد الأنف (احتقان الأنف).<br />&bull; ارتفاع ضغط الدَّم.<br />&bull; صعوبة في التركیز.<br />&bull; ارتجاف أو ارتعاش.<br />&bull; انخفاض الرغبة الجنسیة.<br />&bull; رنین في الأذنین.<br />&bull; تَغَیُّمُ الرُّؤْیَة<br />&bull; عُسْر الھَضْم<br />&bull; جفاف الفم.<br />آثار جانبیة غیر شائعة (قد تُؤثر على ما یصل إلى مریض واحد من بین كل ۱۰۰ مریض):<br />&bull; إغماء أو شعور بالدوخة عند الوقوف (انظر النصائح الواردة أعلاه).<br />&bull; تغیر في الحالة المزاجیة أو شعور بفرط الاستثارة أو جنون الارتیاب.<br />&bull; شعور بالارتباك أو التوھان أو عدم القدرة على التفكیر بوضوح.<br />&bull; بطء ضربات القلب أو عدم انتظامھا أو زیادة معدل ضربات القلب.<br />&bull; فقدان الرغبة الجنسیة ومشاكل في الوصول إلى ذروة الجماع.<br />&bull; شعور بالضعف أو السكون أو الخمول أو الإرھاق.<br />&bull; شعور بالاكتئاب أو التَّوتر أو اللامبالاة.<br />&bull; شعور بحرارة أو بعصبیة أو بإحساس غیر طبیعي أو بالثمالة.<br />&bull; مشاكل في الرؤیة أو ألم بالعین أو اتساع بحدقتي العینین.<br />&bull; ضغط دم مرتفع أو منخفض.<br />&bull; شعور بحكة أو بتعرق بارد.<br />&bull; شعور بالدوار.<br />&bull; إحساس بمذاق غیر طبیعي.<br />&bull; احتكاك الأسنان.<br />آثار جانبیة نادرة (قد تُؤثر على ما یصل إلى مریض واحد من بین كل ۱۰۰۰ مریض):<br />&bull; شعور بالدوخة عقب بذل مجھود.<br />&bull; نوم مفاجئ.<br />&bull; سرعة في حركة الأمعاء.<br />الإبلاغ عن الآثار الجانبیة<br />إذا أُصبت بأیة آثار جانبیة، استشر الطبیب المعالج لك أو الصیدلي ویشمل ھذا الأمر أیة آثار<br />جانبیة مُحتمَلة غیر مُدرجة في ھذه النشرة.<br />من خلال إبلاغك عن آثار جانبیة، یمكنك المساعدة في توفیر معلومات إضافیة حول أمان<br />استخدام ھذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یُحفظ بعیدًا عن مُتناوَل و مرأى الأطفال.<br />یُحفظ في درجة حرارة لا تزید عن ۳۰ درجة مئویة.<br />.&quot;EXP&quot; لا تستعمل ھذا الدَّواء بعد انتھاء تاریخ انتھاء الصلاحیة المدون على العبوة بعد كلمة<br />لا تتخلص من الأدویة عن طریق إلقائھا في میاه الصرف أو مع المخلفات المنزلیة. استشر<br />الصیدلي الخاص بك حول كیفیة التَّخلص من الأدویة التي لم تعد تستخدمھا. تُساعد ھذه<br />الإجراءات في الحفاظ على البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>على ماذا یحتوي دابوكس<br />المادة الفعالة ھي دابوكسیتین: یحتوي كل قرص على ۳۰ ملجم أو ٦۰ ملجم من دابوكسیتین<br />على ھیئة ملح ھیدروكلورید.<br />تشمل المكونات الأخرى ما یلي:<br />قلب القرص: لاكتوز أحادي الھیدرات ، سلیلوز دقیق التبلور، كروس كارمیلوز الصودیوم ،<br />ثاني أكسید السیلیكون الغروي وستیرات الماغنسیوم.<br />الطبقة الخارجیة للقرص: لاكتوز أحادي الھیدرات، ھیبرومیلوز، ثاني أكسید التیتانیوم ، ثلاثي<br />الأستین ، أكسید الحدید الأسود و أكسید الحدید الأصفر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">۰ ملجم أقراص مغلفة ھي أقراص لونھا رمادي فاتح ، مستدیرة الشكل ، محفور &trade; دابوكس<br />و مستویة علي الجانب. &#39;JPAV&#39; على أحد جانبیھا<br />٦۰ ملجم أقراص مغلفة ھي أقراص لونھا رمادي ، مستدیرة الشكل ، محفور على &trade; دابوكس<br />و مستویة علي الجانب. &#39;JPAW&#39; أ حد جانبیھا<br />أقراص مغلفة متوفرة في أقراص ۳۰ ملجم و ٦۰ ملجم في علب تحتوي كل علبة على ٤ &trade; دابوكس<br />أقراص.<br />قد لا تكون كل العبوات مطروحة بالسوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة مصنع جمجوم للأدویة ،<br />جدة، منطقة مكة، المملكة العربیة السعودیة.<br />+۹٦٦-۱۲- الھاتف: ٦۰۸۱۱۱۱<br />+۹٦٦-۱۲- فاكس: ٦۰۸۱۲۲۲<br />www.jamjoompharma.com : الموقع الإلكتروني<br />للإبلاغ عن أي أثار جانبیھ:<br />&bull; المملكة العربیة السعودیة:<br />:(NPC) المركز الوطني للتیقظ الدوائي<br />+۹٦٦-۱۱-۲۰٥- فاكس: ۷٦٦۲ o<br />مركز اتصال الھیئة العامة للغذاء والدواء: ۱۹۹۹۹ o<br />npc.drug@sfda.gov.sa : برید إلكتروني o<br />https://ade.sfda.gov.sa : الموقع الالكتروني o<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04/2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dapox 30 mg Film Coated Tablet
Dapox 60 mg Film Coated Tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each Film Coated tablet contains dapoxetine hydrochloride equivalent to 30 mg or 60 mg
dapoxetine.
Excipient with known effect: Lactose. Each 30 mg tablet contains 43.00 mg of Lactose
Monohydrate. Each 60 mg tablet contains 86.00 mg of Lactose Monohydrate.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film Coated Tablets
30 mg:
Commercial Batches: Light Grey, round shaped, film coated tablets, debossed with "JPAV" on
one side and plain on other side.
Exhibit Batches: Light Grey, round shaped, film coated tablets, debossed with "JPAA" on one
side and plain on other side.
60 mg:
Commercial Batches: Grey, round shaped, film coated tablets, debossed with "JPAW" on one
side and plain on other side.
Exhibit Batches: Grey, round shaped, film coated tablets, debossed with "JP118" on one side and
plain on other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dapoxetine tablets is indicated for the treatment of premature ejaculation (PE) in adult men aged<br />18 to 64 years.<br />Dapoxetine tablets should only be prescribed to patients who meet all the following criteria:<br />&bull; An intravaginal ejaculatory latency time (IELT) of less than two minutes; and<br />&bull; Persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after<br />penetration and before the patient wishes; and<br />&bull; Marked personal distress or interpersonal difficulty as a consequence of PE; and<br />&bull; Poor control over ejaculation; and&nbsp;</p><p>&bull; A history of premature ejaculation in the majority of intercourse attempts over the prior 6<br />months.<br />Dapoxetine tablets should be administered only as on-demand treatment before anticipated sexual<br />activity. Dapoxetine tablets should not be prescribed to delay ejaculation in men who have not<br />been diagnosed with PE.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Adult men (aged 18 to 64 years)<br />The recommended starting dose for all patients is 30 mg, taken as needed approximately 1 to 3<br />hours prior to sexual activity. Treatment with Dapoxetine tablets should not be initiated with the<br />60 mg dose.<br />Dapoxetine tablets is not intended for continuous daily use. Dapoxetine tablets should be taken<br />only when sexual activity is anticipated. Dapoxetine tablets must not be taken more frequently<br />than once every 24 hours.<br />If the individual response to 30 mg is insufficient and the patient has not experienced moderate or<br />severe adverse reactions or prodromal symptoms suggestive of syncope, the dose may be<br />increased to a maximum recommended dose of 60 mg taken as needed approximately 1 to 3 hours<br />prior to sexual activity. The incidence and severity of adverse events is higher with the 60 mg<br />dose.<br />If the patient experienced orthostatic reactions on the starting dose, no dose escalation to 60 mg<br />should be performed (see section 4.4).<br />A careful appraisal of individual benefit risk of Dapoxetine tablets should be performed by the<br />physician after the first four weeks of treatment (or at least after 6 doses of treatment) to<br />determine whether continuing treatment with Dapoxetine tablets is appropriate.<br />Data regarding the efficacy and safety of Dapoxetine tablets beyond 24 weeks are limited. The<br />clinical need of continuing and the benefit risk balance of treatment with Dapoxetine tablets<br />should be re-evaluated at least every six months.<br />Elderly (age 65 years and over)<br />The efficacy and safety of Dapoxetine tablets have not been established in patient&rsquo;s age 65 years<br />and over (see section 5.2).<br />Paediatric population<br />There is no relevant use of Dapoxetine tablets in this population in the indication of premature<br />ejaculation.<br />Patients with renal impairment<br />Caution is advised in patients with mild or moderate renal impairment. Dapoxetine tablets is not<br />recommended for use in patients with severe renal impairment (see sections 4.4 and 5.2).</p><p>Patients with hepatic impairment<br />Dapoxetine tablets is contraindicated in patients with moderate and severe hepatic impairment<br />(Child&minus;Pugh Class B and C) (see sections 4.3 and 5.2).<br />Known CYP2D6 poor metabolizers or patients treated with potent CYP2D6 inhibitors<br />Caution is advised if increasing the dose to 60 mg in patients known to be of CYP2D6 poor<br />metabolizer genotype or in patients concomitantly treated with potent CYP2D6 inhibitors (see<br />sections 4.4, 4.5 and 5.2).<br />Patients treated with moderate or potent inhibitors of CYP3A4<br />Concomitant use of potent CYP3A4 inhibitors is contraindicated. The dose should be restricted to<br />30 mg in patients concomitantly treated with moderate CYP3A4 inhibitors and caution is advised<br />(see sections 4.3, 4.4 and 4.5).<br />Method of administration<br />For oral use. Tablets should be swallowed whole to avoid the bitter taste. It is recommended that<br />tablets be taken with at least one full glass of water. Dapoxetine tablets may be taken with or<br />without food (see section 5.2).<br />Precautions to be taken before handling or administering the medicinal product<br />Before treatment is initiated, see section 4.4 regarding orthostatic hypotension.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Significant pathological cardiac conditions such as:
• Heart failure (NYHA class II-IV)
• Conduction abnormalities such as AV block or sick sinus syndrome
• Significant ischemic heart disease
• Significant valvular disease
• A history of syncope.
A history of mania or severe depression.
Concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days of
discontinuing treatment with an MAOI. Similarly, an MAOI should not be administered within 7
days after Dapoxetine tablets has been discontinued (see section 4.5).
Concomitant treatment with thioridazine, or within 14 days of discontinuing treatment with
thioridazine. Similarly, thioridazine should not be administered within 7 days after Dapoxetine
tablets has been discontinued (see section 4.5).
Concomitant treatment with serotonin reuptake inhibitors [selective serotonin reuptake inhibitors
(SSRIs), serotonin−norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs)]
or other medicinal/herbal products with serotonergic effects [e.g., L−tryptophan, triptans,
tramadol, linezolid, lithium, St. John's Wort (Hypericum perforatum)] or within 14 days of
discontinuing treatment with these medicinal/herbal products. Similarly, these medicinal/herbal
products should not be administered within 7 days after Dapoxetine tablets has been discontinued
(see section 4.5).
Concomitant treatment of potent CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir,
saquinavir, telithromycin, nefazadone, nelfinavir, atazanavir, etc. (see section 4.5).
Moderate and severe hepatic impairment.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General recommendations<br />Dapoxetine tablets is only indicated in men with Premature Ejaculation who meet all the criteria<br />listed in sections 4.1 and 5.1. Dapoxetine tablets should not be prescribed to men who have not<br />been diagnosed with Premature Ejaculation. Safety has not been established and there are no data<br />on the ejaculation&minus;delaying effects in men without Premature Ejaculation.<br />Other forms of sexual dysfunction<br />Before treatment, subjects with other forms of sexual dysfunction, including erectile dysfunction,<br />should be carefully investigated by physicians. Dapoxetine tablets should not be used in men with<br />erectile dysfunction (ED) who are using PDE5 inhibitors (see section 4.5).<br />Orthostatic hypotension<br />Before treatment initiation, a careful medical examination including history of orthostatic events<br />should be performed by the physician. An orthostatic test should be performed before initiating<br />therapy (blood pressure and pulse rate, supine and standing). In case of a history of documented or<br />suspected orthostatic reaction, treatment with Dapoxetine tablets should be avoided.<br />Orthostatic hypotension has been reported in clinical trials. The prescriber should counsel the<br />patient in advance that if he experiences possibly prodromal symptoms, such as lightheadedness<br />soon after standing, he should immediately lie down so his head is lower than the rest of his body<br />or sit down with his head between his knees until the symptoms pass. The prescriber should also<br />inform the patient not to rise quickly after prolonged lying or sitting.<br />Suicide/suicidal thoughts<br />Antidepressants, including SSRIs, increased the risk compared to placebo of suicidal thinking and<br />suicidality in short-term studies in children and adolescents with Major Depressive Disorder and<br />other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality<br />with antidepressants compared to placebo in adults beyond age 24. In clinical trials with<br />Dapoxetine tablets for the treatment of premature ejaculation, there was no clear indication of<br />treatment-emergent suicidality in evaluation of possibly suicide-related adverse events evaluated<br />by the Columbia Classification Algorhythm of Suicide Assessment (C-CASA), Montgomery-<br />Asberg Depression Rating Scale, or Beck Depression Inventory-II.<br />Syncope</p><p>Patients should be cautioned to avoid situations where injury could result, including driving or<br />operating hazardous machinery, should syncope or its prodromal symptoms such as dizziness or<br />lightheadedness occur (see section 4.8).<br />Possibly prodromal symptoms such as nausea, dizziness/lightheadedness, and diaphoresis were<br />reported more frequently among patients treated with Dapoxetine tablets compared to placebo.<br />In the clinical trials, cases of syncope characterized as loss of consciousness, with bradycardia or<br />sinus arrest observed in patients wearing Holter monitors,were considered vasovagal in etiology and<br />the majority occurred during the first 3 hours after dosing, after the first dose, or associated with<br />study&minus;related procedures in the clinic setting (such as blood draw and orthostatic maneuvers and<br />blood pressure measurements). Possibly prodromal symptoms, such as nausea, dizziness,<br />lightheadedness, palpitations, asthenia, confusion and diaphoresis generally occurred within the first<br />3 hours following dosing, and often preceded the syncope. Patients need to be made aware that they<br />could experience syncope at any time with or without prodromal symptoms during their treatment<br />with Dapoxetine tablets. Prescribers should counsel patients about the importance of maintaining<br />adequate hydration and about how to recognize prodromal signs and symptoms to decrease the<br />likelihood of serious injury associated with falls due to loss of consciousness. If the patient<br />experiences possibly prodromal symptoms, the patient should immediately lie down so his head is<br />lower than the rest of his body or sit down with his head between his knees until the symptoms pass,<br />and be cautioned to avoid situations where injury could result, including driving or operating<br />hazardous machinery, should syncope or other CNS effects occur (see section 4.7).<br />Patients with cardiovascular risk factors<br />Subjects with underlying cardiovascular disease were excluded from Phase 3 clinical trials. The risk<br />of adverse cardiovascular outcomes from syncope (cardiac syncope and syncope from other causes)<br />is increased in patients with underlying structural cardiovascular disease (e.g., documented outflow<br />obstruction, valvular heart disease, carotid stenosis and coronary artery disease). There are<br />insufficient data to determine whether this increased risk extends to vasovagal syncope in patients<br />with underlying cardiovascular disease.<br />Use with recreational drugs<br />Patients should be advised not to use Dapoxetine tablets in combination with recreational drugs.<br />Recreational drugs with serotonergic activity such as ketamine, methylenedioxymethamphetamine<br />(MDMA) and lysergic acid diethylamide (LSD) may lead to potentially serious reactions if<br />combined with Dapoxetine tablets. These reactions include, but are not limited to, arrhythmia,<br />hyperthermia, and serotonin syndrome. Use of Dapoxetine tablets with recreational drugs with<br />sedative properties such as narcotics and benzodiazepines may further increase somnolence and<br />dizziness.<br />Ethanol<br />Patients should be advised not to use Dapoxetine tablets in combination with alcohol.<br />Combining alcohol with dapoxetine may increase alcohol&minus;related neurocognitive effects and may<br />also enhance neurocardiogenic adverse events such as syncope, thereby increasing the risk of<br />accidental injury; therefore, patients should be advised to avoid alcohol while taking Dapoxetine<br />tablets (see sections 4.5 and 4.7).</p><p>Medicinal products with vasodilatation properties<br />Dapoxetine tablets should be prescribed with caution in patients taking medicinal products with<br />vasodilatation properties (such as alpha adrenergic receptor antagonists and nitrates) due to possible<br />reduced orthostatic tolerance (see section 4.5).<br />Moderate CYP3A4 inhibitors<br />Caution is advised in patients taking moderate CYP3A4 inhibitors and the dose is restricted to 30 mg<br />(see sections 4.2 and 4.5).<br />Potent CYP2D6 inhibitors<br />Caution is advised if increasing the dose to 60 mg in patients taking potent CYP2D6 inhibitors or if<br />increasing the dose to 60 mg in patients known to be of CYP2D6 poor metabolizer genotype, as this<br />may increase exposure levels, which may result in a higher incidence and severity of dose dependent<br />adverse events (see sections 4.2, 4.5 and 5.2).<br />Mania<br />Dapoxetine tablets should not be used in patients with a history of mania/hypomania or bipolar<br />disorder and should be discontinued in any patient who develops symptoms of these disorders.<br />Seizure<br />Due to the potential of SSRIs to lower the seizure threshold, Dapoxetine tablets should be<br />discontinued in any patient who develops seizures and avoided in patients with unstable epilepsy.<br />Patients with controlled epilepsy should be carefully monitored.<br />Paediatric population<br />Dapoxetine tablets should not be used in individuals below 18 years of age.<br />Depression and/or psychiatric disorders<br />Men with underlying signs and symptoms of depression should be evaluated prior to treatment with<br />Dapoxetine tablets to rule out undiagnosed depressive disorders. Concomitant treatment of<br />Dapoxetine tablets with antidepressants, including SSRIs and SNRIs, is contraindicated (see section<br />4.3). Discontinuation of treatment for ongoing depression or anxiety in order to initiate Dapoxetine<br />tablets for the treatment of PE is not recommended. Dapoxetine tablets is not indicated for<br />psychiatric disorders and should not be used in men with these disorders, such as schizophrenia, or<br />in those suffering with co&minus;morbid depression, as worsening of symptoms associated with depression<br />cannot be excluded. This could be the result of underlying psychiatric disorder or might be a result<br />of medicinal product therapy. Physicians should encourage patients to report any distressing<br />thoughts or feelings at any time and if signs and symptoms of depression develop during treatment,<br />Dapoxetine tablets should be discontinued.<br />Haemorrhage<br />There have been reports of bleeding abnormalities with SSRIs. Caution is advised in patients taking<br />Dapoxetine tablets , particularly in concomitant use with medicinal products known to affect platelet<br />function (e.g., atypical antipsychotics and phenothiazines, acetylsalicylic acid, nonsteroidal&nbsp;anti&minus;inflammatory drugs [NSAIDs], anti&minus;platelet agents) or anticoagulants (e.g., warfarin), as well<br />as in patients with a history of bleeding or coagulation disorders (see section 4.5).<br />Renal impairment<br />Dapoxetine tablets is not recommended for use in patients with severe renal impairment and caution<br />is advised in patients with mild or moderate renal impairment (see sections 4.2 and 5.2).<br />Withdrawal effects<br />Abrupt discontinuation of chronically administered SSRIs used to treat chronic depressive disorders<br />has been reported to result in the following symptoms: dysphoric mood, irritability, agitation,<br />dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety,<br />confusion, headache, lethargy, emotional lability, insomnia and hypomania.<br />A double&minus;blind clinical trial in subjects with PE designed to assess the withdrawal effects of 62 days<br />of daily or as needed dosing with 60 mg Dapoxetine tablets showed mild withdrawal symptoms with<br />a slightly higher incidence of insomnia and dizziness in subjects switched to placebo after daily<br />dosing (see section 5.1).<br />Eye disorders<br />The use of Dapoxetine tablets has been associated with ocular effects such as mydriasis and eye<br />pain. Dapoxetine tablets should be used with caution in patients with raised intraocular pressure or<br />those at risk of angle closure glaucoma.<br />Lactose intolerance<br />Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or<br />glucose&minus;galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacodynamic interactions<br />Potential for interaction with monoamine oxidase inhibitors<br />In patients receiving an SSRI in combination with a monoamine oxidase inhibitor (MAOI), there<br />have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity,<br />myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status<br />changes that include extreme agitation progressing to delirium and coma. These reactions have also<br />been reported in patients who have recently discontinued an SSRI and have been started on an<br />MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Animal<br />data on the effects of combined use of an SSRI and MAOIs suggest that these medicinal products<br />may act synergistically to elevate blood pressure and evoke behavioural excitation. Therefore,<br />Dapoxetine tablets should not be used in combination with an MAOI, or within 14 days of<br />discontinuing treatment with an MAOI. Similarly, an MAOI should not be administered within 7<br />days after Dapoxetine tablets has been discontinued (see section 4.3).<br />Potential for interaction with thioridazine</p><p>Thioridazine administration alone produces prolongation of the QTc interval, which is associated<br />with serious ventricular arrhythmias. Medicinal products such as Dapoxetine tablets that inhibit the<br />CYP2D6 isoenzyme appear to inhibit the metabolism of thioridazine and the resulting elevated<br />levels of thioridazine are expected to augment the prolongation of the QTc interval. Dapoxetine<br />tablets should not be used in combination with thioridazine or within 14 days of discontinuing<br />treatment with thioridazine. Similarly, thioridazine should not be administered within 7 days after<br />Dapoxetine tablets has been discontinued (see section 4.3).<br />Medicinal/herbal products with serotonergic effects<br />As with other SSRIs, co&minus;administration with serotonergic medicinal/herbal products (including<br />MAOIs, L&minus;tryptophan, triptans, tramadol, linezolid, SSRIs, SNRIs, lithium and St. John&#39;s Wort<br />(Hypericum perforatum) preparations) may lead to an incidence of serotonin associated effects.<br />Dapoxetine tablets should not be used in combination with other SSRIs, MAOIs or other<br />serotonergic medicinal/herbal products or within 14 days of discontinuing treatment with these<br />medicinal/herbal products. Similarly, these medicinal/herbal products should not be administered<br />within 7 days after Dapoxetine tablets has been discontinued (see section 4.3).<br />CNS active medicinal products<br />The use of Dapoxetine tablets in combination with CNS active medicinal products (e.g.,<br />antiepileptics, antidepressants, antipsychotics, anxiolytics, sedative hypnotics) has not been<br />systematically evaluated in patients with premature ejaculation. Consequently, caution is advised if<br />the concomitant administration of Dapoxetine tablets and such medicinal products is required.<br />Pharmacokinetic interactions<br />Effects of co&minus;administered medicinal products on the pharmacokinetics of dapoxetine<br />In vitro studies in human liver, kidney, and intestinal microsomes indicate dapoxetine is<br />metabolized primarily by CYP2D6, CYP3A4 and flavin monooxygenase 1 (FMO1). Therefore,<br />inhibitors of these enzymes may reduce dapoxetine clearance.<br />CYP3A4 inhibitors<br />Potent CYP3A4 inhibitors. Administration of ketoconazole (200 mg twice daily for 7 days)<br />increased the Cmax and AUCinf of dapoxetine (60 mg single dose) by 35% and 99%, respectively.<br />Considering the contribution of both unbound dapoxetine and desmethyldapoxetine, the Cmax of<br />the active fraction may be increased by approximately 25% and the AUC of the active fraction may<br />be doubled if taken with potent CYP3A4 inhibitors.<br />The increases in the Cmax and AUC of the active fraction may be markedly increased in a part of<br />the population which lack a functional CYP2D6 enzyme, i.e., CYP2D6 poor metabolizers, or in<br />combination with potent inhibitors of CYP2D6.<br />Therefore, concomitant use of Dapoxetine tablets and potent CYP3A4 inhibitors, such as<br />ketoconazole, itraconazole, ritonavir, saquinavir, telithromycin, nefazodone, nelfinavir and<br />atazanavir, is contraindicated (see section 4.3).<br />Moderate CYP3A4 inhibitors. Concomitant treatment with moderate CYP3A4 inhibitors (e.g.,<br />erythromycin, clarithromycin, fluconazole, amprenavir, fosamprenavir, aprepitant, verapamil,<br />diltiazem) may also give rise to significantly increased exposure of dapoxetine and&nbsp;desmethyldapoxetine, especially in CYP2D6 poor metabolizers. The maximum dose of dapoxetine<br />should be 30 mg if dapoxetine is combined with any of these drugs (see sections 4.2, 4.4 and<br />below).<br />These two measures apply to all patients unless the patient has been verified to be a CYP2D6<br />extensive metabolizer by geno&minus; or phenotyping. In patients verified to be CYP2D6 extensive<br />metabolizers, a maximum dose of 30 mg is advised if dapoxetine is combined with a potent<br />CYP3A4 inhibitor and caution is advised if dapoxetine in 60 mg doses is taken concomitantly with<br />a moderate CYP3A4 inhibitor.<br />Potent CYP2D6 inhibitors<br />The Cmax and AUCinf of dapoxetine (60 mg single dose) increased by 50% and 88%, respectively,<br />in the presence of fluoxetine (60 mg/day for 7 days). Considering the contribution of both unbound<br />dapoxetine and desmethyldapoxetine, the Cmax of the active fraction may be increased by<br />approximately 50% and the AUC of the active fraction may be doubled if taken with potent<br />CYP2D6 inhibitors. These increases in the Cmax and AUC of the active fraction are similar to<br />those expected for CYP2D6 poor metabolizers and may result in a higher incidence and severity of<br />dose dependent adverse events (see section 4.4).<br />PDE5 inhibitors<br />Dapoxetine tablets should not be used in patients using PDE5 inhibitors due to possible reduced<br />orthostatic tolerance (see section 4.4). The pharmacokinetics of dapoxetine (60 mg) in combination<br />with tadalafil (20 mg) and sildenafil (100 mg) were evaluated in a single dose crossover study.<br />Tadalafil did not affect the pharmacokinetics of dapoxetine. Sildenafil caused slight changes in<br />dapoxetine pharmacokinetics (22% increase in AUCinf and 4% increase in Cmax), which are not<br />expected to be clinically significant.<br />Concomitant use of Dapoxetine tablets with PDE5 inhibitors may result in orthostatic hypotension<br />(see section 4.4). The efficacy and safety of Dapoxetine tablets in patients with both premature<br />ejaculation and erectile dysfunction concomitantly treated with Dapoxetine tablets and PDE5<br />inhibitors have not been established.<br />Effects of dapoxetine on the pharmacokinetics of co &minus;administered medicinal products<br />Tamsulosin<br />Concomitant administration of single or multiple doses of 30 mg or 60 mg dapoxetine to patients<br />receiving daily doses of tamsulosin did not result in changes in the pharmacokinetics of tamsulosin.<br />The addition of dapoxetine to tamsulosin did not result in a change in the orthostatic profile and<br />there were no differences in orthostatic effects between tamsulosin combined with either 30 or 60<br />mg dapoxetine and tamsulosin alone; however, Dapoxetine tablets should be prescribed with<br />caution in patients who use alpha adrenergic receptor antagonists due to possible reduced<br />orthostatic tolerance (see section 4.4).<br />Medicinal products metabolized by CYP2D6<br />Multiple doses of dapoxetine (60 mg/day for 6 days) followed by a single 50 mg dose of<br />desipramine increased the mean Cmax and AUCinf of desipramine by approximately 11% and<br />19%, respectively, compared to desipramine administered alone. Dapoxetine may give rise to a&nbsp;similar increase in the plasma concentrations of other drugs metabolized by CYP2D6. The clinical<br />relevance is likely to be small.<br />Medicinal products metabolized by CYP3A4<br />Multiple dosing of dapoxetine (60 mg/day for 6 days) decreased the AUCinf of midazolam (8 mg<br />single dose) by approximately 20% (range &minus;60 to +18%). The clinical relevance of the effect on<br />midazolam is likely to be small in most patients. The increase in CYP3A activity may be of clinical<br />relevance in some individuals concomitantly treated with a medicinal product mainly metabolized<br />by CYP3A and with a narrow therapeutic window.<br />Medicinal products metabolized by CYP2C19<br />Multiple dosing of dapoxetine (60 mg/day for 6 days) did not inhibit the metabolism of a single 40<br />mg dose of omeprazole. Dapoxetine is unlikely to affect the pharmacokinetics of other CYP2C19<br />substrates.<br />Medicinal products metabolized by CYP2C9<br />Multiple dosing of dapoxetine (60 mg/day for 6 days) did not affect the pharmacokinetics or<br />pharmacodynamics of a single 5 mg dose of glyburide. Dapoxetine is unlikely to affect the<br />pharmacokinetics of other CYP2C9 substrates.<br />Warfarin and medicinal products that are known to affect coagulation and/or platelet function<br />There are no data evaluating the effect of chronic use of warfarin with dapoxetine; therefore,<br />caution is advised when dapoxetine is used in patients taking warfarin chronically (see section 4.4).<br />In a pharmacokinetic study, dapoxetine (60 mg/day for 6 days) did not affect the pharmacokinetics<br />or pharmacodynamics (PT or INR) of warfarin following a single 25 mg dose.<br />There have been reports of bleeding abnormalities with SSRIs (see section 4.4).<br />Ethanol<br />Coadministration of a single dose of ethanol, 0.5 g/kg (approximately 2 drinks), did not affect the<br />pharmacokinetics of dapoxetine (60 mg single dose); however, dapoxetine in combination with<br />ethanol increased somnolence and significantly decreased self&minus;rated alertness. Pharmacodynamic<br />measures of cognitive impairment (Digit Vigilance Speed, Digit Symbol Substitution Test) also<br />showed an additive effect when dapoxetine was coadministered with ethanol. Concomitant use of<br />alcohol and dapoxetine increases the chance or severity of adverse reactions such as dizziness,<br />drowsiness, slow reflexes, or altered judgment. Combining alcohol with dapoxetine may increase<br />these alcohol&minus;related effects and may also enhance neurocardiogenic adverse events such as<br />syncope, thereby increasing the risk of accidental injury; therefore, patients should be advised to<br />avoid alcohol while taking Dapoxetine tablets (see sections 4.4 and 4.7).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dapoxetine tablets is not indicated for use by women.<br />Animal studies do not indicate direct or indirect harmful effects with respect to fertility, pregnancy<br />or embryonal/foetal development (see section 5.3).</p><p>It is not known if either dapoxetine or its metabolites are excreted in human milk.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dapoxetine tablets has minor or moderate influence on the ability to drive and use machines.<br />Dizziness, disturbance in attention, syncope, blurred vision and somnolence have been reported in<br />subjects receiving dapoxetine in clinical trials. Therefore, patients should be warned to avoid<br />situations where injury could result, including driving or operating hazardous machinery.<br />Combining alcohol with dapoxetine may increase alcohol&minus;related neurocognitive effects and may<br />also enhance neurocardiogenic adverse events such as syncope, thereby increasing the risk of<br />accidental injury; therefore, patients should be advised to avoid alcohol while taking Dapoxetine<br />tablets (see sections 4.4 and 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />Syncope and orthostatic hypotension have been reported in clinical trials (see section 4.4).<br />The following adverse drug reactions were reported during Phase 3 clinical trials most commonly<br />and were dose related: nausea (11.0% and 22.2% in 30 mg and 60 mg prn dapoxetine groups,<br />respectively), dizziness (5.8% and 10.9%), headache (5.6% and 8.8%), diarrhoea (3.5% and 6.9%),<br />insomnia (2.1% and 3.9%) and fatigue (2.0% and 4.1%). The most common adverse events leading<br />to discontinuation were nausea (2.2% of Dapoxetine tablets &minus;treated subjects) and dizziness (1.2%<br />of Dapoxetine tablets &minus;treated subjects).<br />Tabulated list of adverse reactions<br />The safety of Dapoxetine tablets was evaluated in 4224 subjects with premature ejaculation who<br />participated in five double&minus;blind, placebo&minus;controlled clinical trials. Of the 4224 subjects, 1616<br />received Dapoxetine tablets 30 mg as needed and 2608 received 60 mg, either as needed or once<br />daily.<br />Table 1 presents the adverse reactions that have been reported.</p><p>Adverse drug reactions reported in the 9-month long&minus;term open&minus;label extension trial were<br />consistent with those reported in the double&minus;blind studies and no additional adverse drug reactions<br />were reported.</p><p>Description of selected adverse reactions<br />Syncope characterized as loss of consciousness, with bradycardia or sinus arrest observed in patients<br />wearing Holter monitors, has been reported in clinical trials and is considered medicinal productrelated.<br />The majority of cases occurred during the first 3 hours after dosing, after the first dose or<br />associated with study-related procedures in the clinical setting (such as blood draw and orthostatic<br />maneuvers and blood pressure measurements). Prodromal symptoms often preceded the syncope<br />(see section 4.4).<br />The occurrence of syncope and possibly prodromal symptoms appears dose dependent as<br />demonstrated by higher incidence among patients treated with higher than recommended doses in<br />Phase 3 clinical trials.<br />Orthostatic hypotension has been reported in clinical trials (see section 4.4).The frequency of<br />syncope characterized as loss of consciousness in the Dapoxetine tablets clinical development<br />program varied depending on the population studied and ranged from 0.06% (30 mg) to 0.23% (60<br />mg) for subjects enrolled in the Phase 3 placebo-controlled clinical trials to 0.64% (all doses<br />combined) for Phase 1 non-PE healthy volunteer studies.<br />Other special populations<br />Caution is advised if increasing the dose to 60 mg in patients taking potent CYP2D6 inhibitors or if<br />increasing the dose to 60 mg in patients known to be of CYP2D6 poor metabolizer genotype (see<br />sections 4.2, 4.4, 4.5 and 5.2).<br />Withdrawal effects<br />Abrupt discontinuation of chronically administered SSRIs used to treat chronic depressive disorders<br />has been reported to result in the following symptoms: dysphoric mood, irritability, agitation,<br />dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety,<br />confusion, headache, lethargy, emotional lability, insomnia and hypomania.<br />Results of a safety study showed a slightly higher incidence of withdrawal symptoms of mild or<br />moderate insomnia and dizziness in subjects switched to placebo after 62 days of daily dosing.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No case of overdose has been reported.<br />There were no unexpected adverse events in a clinical pharmacology study of Dapoxetine tablets<br />with daily doses up to 240 mg (two 120 mg doses given 3 hours apart). In general, symptoms of&nbsp;overdose with SSRIs include serotonin&minus;mediated adverse reactions such as somnolence,<br />gastrointestinal disturbances such as nausea and vomiting, tachycardia, tremor, agitation and<br />dizziness.<br />In cases of overdose, standard supportive measures should be adopted as required. Due to high<br />protein binding and large volume of distribution of dapoxetine hydrochloride, forced diuresis,<br />dialysis, hemoperfusion and exchange transfusion are unlikely to be of benefit. No specific<br />antidotes for Dapoxetine tablets are known.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other Urologicals, ATC code: G04BX14<br />Mechanism of action<br />Dapoxetine is a potent selective serotonin reuptake inhibitor (SSRI) with an IC50 of 1.12 nM, while<br />its major human metabolites, desmethyldapoxetine (IC50 &lt; 1.0 nM) and didesmethyldapoxetine<br />(IC50 = 2.0 nM) are equivalent or less potent (dapoxetine-N-oxide (IC50 = 282 nM)).<br />Human ejaculation is primarily mediated by the sympathetic nervous system. The ejaculatory<br />pathway originates from a spinal reflex centre, mediated by the brain stem, which is influenced<br />initially by a number of nuclei in the brain (medial preoptic and paraventricular nuclei).<br />The mechanism of action of dapoxetine in premature ejaculation is presumed to be linked to the<br />inhibition of neuronal reuptake of serotonin and the subsequent potentiation of the<br />neurotransmitter&#39;s action at pre&minus; and postsynaptic receptors.<br />In the rat, dapoxetine inhibits the ejaculatory expulsion reflex by acting at a supraspinal level<br />within the lateral paragigantocellular nucleus (LPGi). Post ganglionic sympathetic fibers that<br />innervate the seminal vesicles, vas deferens, prostate, bulbourethral muscles and bladder neck<br />cause them to contract in a coordinated fashion to achieve ejaculation. Dapoxetine modulates this<br />ejaculatory reflex in rats.<br />Clinical efficacy and safety<br />The effectiveness of Dapoxetine tablets in the treatment of premature ejaculation has been<br />established in five double&minus;blind, placebo&minus;controlled clinical trials, in which a total of 6081<br />subjects were randomized. Subjects were 18 years of age or older and had a history of PE in the<br />majority of intercourse experiences in the 6&minus;month period prior to enrolment. Premature<br />ejaculation was defined according to the DSM-IV diagnostic criteria: short ejaculatory time (an<br />intravaginal ejaculatory latency time [IELT; time from vaginal penetration to the moment of<br />intravaginal ejaculation] of &le; 2 minutes measured using a stopwatch in four studies), poor control<br />over ejaculation, marked distress or interpersonal difficulty due to the condition.<br />Subjects with other forms of sexual dysfunction, including erectile dysfunction, or those using<br />other forms of pharmacotherapy for the treatment of PE were excluded from all studies.</p><p>Results of all randomized studies were consistent. Efficacy was demonstrated after 12 weeks of<br />treatment. One study enrolled patients both outside and within the EU and had a treatment duration<br />of 24 weeks. In the study, 1162 subjects were randomized, 385 to placebo, 388 to Dapoxetine<br />tablets 30 mg as needed, and 389 to Dapoxetine tablets 60 mg as needed. The mean and median<br />Average IELT at study end are presented in Table 2 below and the cumulative distribution of<br />subjects who achieved at least a specific level in Average IELT at study end are presented in Table<br />3 below. Other studies and pooled analysis of the data at Week 12 gave consistent results.</p><p>The magnitude of IELT prolongation was related to baseline IELT and was variable between<br />individual subjects. The clinical relevance of Dapoxetine tablets treatment effects was further<br />demonstrated in terms of various patient reported outcome measures and a responder analysis.<br />A responder was defined as a subject who had at least a 2&minus;category increase in control over<br />ejaculation plus at least a 1&minus;category decrease in ejaculation&minus;related distress. A statistically<br />significantly greater percentage of subjects responded in each of the Dapoxetine tablets groups<br />versus placebo at the end of the study Week 12 or 24. There was a higher percentage of responders<br />in the dapoxetine 30 mg (11.1% - 95% CI [7.24; 14.87]) and 60 mg (16.4% - 95% CI [13.01;<br />19.75]) groups compared with the placebo group at Week 12 (pooled analysis).<br />The clinical relevance of Dapoxetine tablets treatment effects is represented by treatment group for<br />the subject&#39;s Clinical Global Impression of Change (CGIC) outcome measure, in which patients&nbsp;were asked to compare their premature ejaculation from the start of the study, with response<br />options ranging from much better to much worse. At study end (Week 24), 28.4% (30 mg group)<br />and 35.5% (60 mg group) of subjects reported their condition to be &ldquo;better&rdquo; or &ldquo;much better&rdquo;,<br />compared to 14% for placebo, while 53.4% and 65.6% of subjects treated with dapoxetine 30 mg<br />and 60 mg, respectively, reported their condition to be at least &ldquo;slightly better&rdquo;, compared to<br />28.8% for placebo.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Dapoxetine is rapidly absorbed with maximum plasma concentrations (Cmax) occurring<br />approximately 1-2 hours after tablet intake. The absolute bioavailability is 42% (range 15&minus;76%),<br />and dose proportional increases in exposure (AUC and Cmax) are observed between the 30 and 60<br />mg dose strengths. Following multiple doses, AUC values for both dapoxetine and the active<br />metabolite desmethyldapoxetine (DED) increase by approximately 50% when compared to single<br />dose AUC values.<br />Ingestion of a high fat meal modestly reduced the Cmax (by 10%) and modestly increased the AUC<br />(by 12%) of dapoxetine and slightly delayed the time for dapoxetine to reach peak concentrations.<br />These changes are not clinically significant. Dapoxetine tablets can be taken with or without food.<br />Distribution<br />More than 99% of dapoxetine is bound in vitro to human serum proteins. The active metabolite<br />desmethyldapoxetine (DED) is 98.5% protein bound. Dapoxetine has a mean steady state volume of<br />distribution of 162 L.<br />Biotransformation<br />In vitro studies suggest that dapoxetine is cleared by multiple enzyme systems in the liver and<br />kidneys, primarily CYP2D6, CYP3A4, and flavin monooxygenase (FMO1). Following oral dosing<br />of 14C&minus;dapoxetine, dapoxetine was extensively metabolized to multiple metabolites primarily<br />through the following biotransformational pathways: N&minus;oxidation, N&minus;demethylation, naphthyl<br />hydroxylation, glucuronidation and sulfation. There was evidence of presystemic first&minus;pass<br />metabolism after oral administration.<br />Intact dapoxetine and dapoxetine&minus;N&minus;oxide were the major circulating moieties in the plasma. In<br />vitro binding and transporter studies show that dapoxetine&minus;N&minus;oxide is inactive. Additional<br />metabolites including desmethyldapoxetine and didesmethyldapoxetine account for less than 3% of<br />the total circulating drug &ndash;related materials in plasma. In vitro binding studies indicate that DED is<br />equipotent to dapoxetine and didesmethyldapoxetine has approximately 50% of the potency of<br />dapoxetine (see section 5.1). The unbound exposures (AUC and Cmax) of DED are approximately<br />50% and 23%, respectively, of the unbound exposure of dapoxetine.<br />Elimination<br />The metabolites of dapoxetine were primarily eliminated in the urine as conjugates. Unchanged<br />active substance was not detected in the urine. Following oral administration, dapoxetine has an<br />initial (disposition) half-life of approximately 1.5 hours, with plasma levels less than 5% of peak&nbsp;concentrations by 24 hours post-dose, and a terminal half-life of approximately 19 hours. The<br />terminal half&minus;life of DED is approximately 19 hours.<br />Pharmacokinetics in special populations<br />The metabolite DED contributes to the pharmacological effect of Dapoxetine tablets, particularly<br />when the exposure of DED is increased. Below, in some populations, the increase in active fraction<br />parameters is presented. This is the sum of the unbound exposure of dapoxetine and DED. DED is<br />equipotent to dapoxetine. The estimation assumes equal distribution of DED to the CNS but it is<br />unknown whether this is the case.<br />Race<br />Analyses of single dose clinical pharmacology studies using 60 mg dapoxetine indicated no<br />statistically significant differences between Caucasians, Blacks, Hispanics and Asians. A clinical<br />study conducted to compare the pharmacokinetics of dapoxetine in Japanese and Caucasian<br />subjects showed 10% to 20% higher plasma levels (AUC and peak concentration) of dapoxetine in<br />Japanese subjects due to lower body weight. The slightly higher exposure is not expected to have a<br />meaningful clinical effect.<br />Elderly (age 65 years and over)<br />Analyses of a single dose clinical pharmacology study using 60 mg dapoxetine showed no<br />significant differences in pharmacokinetic parameters (Cmax, AUCinf, Tmax) between healthy elderly<br />males and healthy young adult males. The efficacy and safety has not been established in this<br />population (see section 4.2).<br />Renal impairment<br />A single-dose clinical pharmacology study using a 60 mg dapoxetine dose was conducted in<br />subjects with mild (CrCL 50 to 80 mL/min), moderate (CrCL 30 to &lt; 50 mL/min), and severe renal<br />impairment (CrCL &lt; 30 mL/min) and in subjects with normal renal function (CrCL &gt; 80 mL/min).<br />No clear trend for an increase in dapoxetine AUC with decreasing renal function was observed.<br />AUC in subjects with severe renal impairment was approximately 2-fold that of subjects with<br />normal renal function, although there are limited data in patients with severe renal impairment.<br />Dapoxetine pharmacokinetics have not been evaluated in patients requiring renal dialysis (see<br />sections 4.2 and 4.4).<br />Hepatic impairment<br />In patients with mild hepatic impairment, unbound Cmax of dapoxetine is decreased by 28% and<br />unbound AUC is unchanged. The unbound Cmax and AUC of the active fraction (the sum of the<br />unbound exposure of dapoxetine and desmethyldapoxetine) were decreased by 30% and 5%,<br />repectively. In patients with moderate hepatic impairment, unbound Cmax of dapoxetine is<br />essentially unchanged (decrease of 3%) and unbound AUC is increased by 66%. The unbound<br />Cmax and AUC of the active fraction were essentially unchanged and doubled, respectively.<br />In patients with severe hepatic impairment, the unbound Cmax of dapoxetine was decreased by 42%<br />but the unbound AUC was increased by approximately 223%. The Cmax and AUC of the active<br />fraction had similar changes (see sections 4.2 and 4.3).<br />CYP2D6 Polymorphism&nbsp;In a single dose clinical pharmacology study using 60 mg dapoxetine, plasma concentrations in<br />poor metabolizers of CYP2D6 were higher than in extensive metabolizers of CYP2D6<br />(approximately 31% higher for Cmax and 36% higher for AUCinf of dapoxetine and 98% higher for<br />Cmax and 161% higher for AUCinf of desmethyldapoxetine). The active fraction of Dapoxetine<br />tablets may be increased by approximately 46% at Cmax and by approximately 90% at AUC. This<br />increase may result in a higher incidence and severity of dose dependent adverse events (see section<br />4.2). The safety of Dapoxetine tablets in poor metabolizers of CYP2D6 is of particular concern with<br />concomitant administration of other medicinal products that may inhibit the metabolism of<br />dapoxetine such as moderate and potent CYP3A4 inhibitors (see sections 4.2 and 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A full assessment of the safety pharmacology, repeat dose toxicology, genetic toxicology,<br />carcinogenicity, dependence/withdrawal liability, phototoxicity and developmental reproductive<br />toxicology of dapoxetine was conducted in preclinical species (mouse, rat, rabbit, dog and<br />monkey) up to the maximum tolerated doses in each species. Due to the more rapid bioconversion<br />in the preclinical species than in man, pharmacokinetic exposure indices (Cmax and AUC0&minus; 24 hr)<br />at the maximum tolerated doses in some studies approached those observed in man. However, the<br />body weight normalized dose multiples were greater than 100-fold. There were no clinically<br />relevant safety hazards identified in any of these studies.<br />In studies with oral administration, dapoxetine was not carcinogenic to rats when administered<br />daily for approximately two years at doses up to 225 mg/kg/day, yielding approximately twice the<br />exposures (AUC) seen in human males given the Maximum Recommended Human Dose (MRHD)<br />of 60 mg. Dapoxetine also did not cause tumors in Tg.rasH2 mice when administered at the<br />maximum possible doses of 100 mg/kg for 6 months and 200 mg/kg for 4 months. The steady state<br />exposures of dapoxetine in mice following 6-months oral administration at 100 mg/kg/day were<br />less than the single dose exposures observed clinically at 60 mg.<br />There were no effects on fertility, reproductive performance or reproductive organ morphology in<br />male or female rats and no adverse signs of embryotoxicity or fetotoxicity in the rat or rabbit.<br />Reproductive toxicity studies did not include studies to assess the risk of adverse effects after<br />exposure during the peri-post-natal period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p> Lactose Monohydrate<br /> Microcrystalline Cellulose<br /> Croscarmellose Sodium<br /> Colloidal Silicon Dioxide<br /> Magnesium Stearate</p><p> Opadry II Grey<br /> Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 Months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C.<br />Keep out of reach and sight of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Immediate Container: Alu-PVC/PVDC Blister pack<br />Secondary Container: Carton &amp; PIL</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Factory Company
Plot No: ME1:3 Phase V, Industrial City,
Jeddah, 21442
Tel: +966-12-6081111
Fax: +966-12-6081222.
Kingdom of Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>